https://www.selleckchem.com/products/mira-1.html
To investigate eosinophilia as a potential on-treatment biomarker for patients receiving cancer immunotherapy. We evaluated the association between eosinophilia and treatment response and toxicity in a retrospective cohort of patients receiving cancer immunotherapy. The study involved 146 patients. Eosinophilia developed in 22%. Patients who developed eosinophilia were more likely to achieve disease control (p =0.009), with every 0.1×10 /l rise in eosinophil count, while receiving treatment was associated with a 28% relative increased ch
Like
Comment
Share
